Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Ker Yu"'
Autor:
Li Xia, Enming Tian, Mingcheng Yu, Chenglong Liu, Lian Shen, Yafei Huang, Zhongen Wu, Jinlong Tian, Ker Yu, Yonghui Wang, Qiong Xie, Di Zhu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-23 (2022)
Abstract Background The overall response rate to checkpoint blockade remains unsatisfactory, partially due to the immune-suppressive tumor microenvironment. A retinoic acid-related orphan receptor γt (RORγt) agonist (LYC-55716) is currently used in
Externí odkaz:
https://doaj.org/article/75b90835d1124728851ce9db56e3fc3d
Autor:
Shuhua He, Xiang Gu, Jintong Yang, Fei Xu, Jiachun Hu, Wei Wang, Yiheng Huang, Bin Lou, Tingbo Ding, Lu Zhou, Deyong Ye, Ker Yu, Jibin Dong
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Tumor-associated macrophages (TAMs) are one of the most abundant immune cells in the pancreatic cancer stroma and are related to the poor prognosis of pancreatic ductal adenocarcinoma (PDAC) patients. Therefore, targeting tumor-associated
Externí odkaz:
https://doaj.org/article/f6326105ed07431dafd7f7c6b77fed06
Autor:
Mei Feng, Zhongen Wu, Yan Zhou, Zhuang Wei, Enming Tian, Shenglin Mei, Yuanyuan Zhu, Chenglong Liu, Fenglian He, Huiyu Li, Cao Xie, Joy Jin, Jibin Dong, Dehua Yang, Ker Yu, Junbin Qian, Diether Lambrechts, Ming-Wei Wang, Di Zhu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 6, Iss 1, Pp 1-14 (2021)
Abstract To date, the overall response rate of PD-1 blockade remains unsatisfactory, partially due to limited understanding of tumor immune microenvironment (TIME). B-cell lymphoma 9 (BCL9), a key transcription co-activator of the Wnt pathway, is hig
Externí odkaz:
https://doaj.org/article/d74d6c50bfa84e0791095b5a904f6f86
Autor:
Jin-peng Pei, Yue Wang, Lan-ping Ma, Xin Wang, Liang Liu, Yu Zhang, Rui Jin, Zhi-qiang Ren, Yan Deng, Jing-kang Shen, Tao Meng, Ker Yu
Publikováno v:
Acta Pharmacologica Sinica. 44:1290-1303
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0b9fe5d61534ee79e94286a5a46c145
https://doi.org/10.1038/s41401-022-01047-6
https://doi.org/10.1038/s41401-022-01047-6
Autor:
Mengzhen Lai, Tao Zhang, Hao Chen, Peiran Song, Linjiang Tong, Jiaying Chen, Yingqiang Liu, Yi Ning, Fang Feng, Yan Li, Haotian Tang, Yi Chen, Yan Fang, Xiaoyun Lu, Meiyu Geng, Ke Ding, Ker Yu, Jian Ding, Hua Xie
Publikováno v:
Journal of Cancer. 14:152-162
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fd63813bb2a5f6f962dd06fcd7e20ea
https://doi.org/10.7150/jca.77788
https://doi.org/10.7150/jca.77788
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Mechanistic target of rapamycin (mTOR) signaling pathway mediates the function of oncogenic receptor tyrosine kinases (RTKs). We aimed to elucidate new role of mTOR in EGFR-mutant (EGFR-mut) non-small cell lung cancer (NSCLC) and glioblastoma (GBM) w
Externí odkaz:
https://doaj.org/article/f5e7cf7491f04a27a29ade194fcfe30d
Mechanism of Regulation of Big-Conductance Ca2+-Activated K+ Channels by mTOR Complex 2 in Podocytes
Autor:
Yinhang Wang, Jie Tao, Mengling Wang, Licai Yang, Fengling Ning, Hong Xin, Xudong Xu, Hui Cai, Weiguang Zhang, Ker Yu, Xuemei Zhang
Publikováno v:
Frontiers in Physiology, Vol 10 (2019)
Podocytes, dynamic polarized cells wrapped around glomerular capillaries, are an essential component of the glomerular filtration barrier. BK channels consist of one of the slit diaphragm (SD) proteins in podocytes, interact with the actin cytoskelet
Externí odkaz:
https://doaj.org/article/e0ad7a0c698d4164a991ce4a03ec5904
Autor:
Ker Yu, Jingkang Shen, Xin Wang, Zhiqiang Ren, Xuesai Zhang, Ying Cong, Jinpeng Pei, Lanping Ma, Tao Meng, Yun Xing, Liang Liu, Rui Jin
Supplementary Figures and Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::024bafa8f0556544368fe792f6e95205
https://doi.org/10.1158/1535-7163.22519333.v1
https://doi.org/10.1158/1535-7163.22519333.v1
Purpose:We aimed to investigate efficacy and mechanism of MTI-31 (LXI-15029), a novel mTORC1/mTORC2 inhibitor currently in human trial (NCT03125746), in non–small cell lung cancer (NSCLC) models of multiple driver mutations and tyrosine kinase inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fc156265bfe37104be8828b9e136074
https://doi.org/10.1158/1078-0432.c.6527214.v1
https://doi.org/10.1158/1078-0432.c.6527214.v1